Urotoday

ProsTIC26: Lu-PSMA Combinations: Which Combo Will Rule?

ProsTIC 2026, Lu-PSMA combinations ENZA-p LuPARP PRINCE EVOLUTION, lutetium-PSMA combination therapy which will rule, ENZA-p enzalutamide luteti…

ProsTIC26: PSMA Imaging and Theranostics in China Today

ProsTIC 2026, PSMA imaging theranostics China regulatory acceleration, China PSMA radioligand therapy approval NMPA FDA gap, lutetium-PSMA-617 C…

ProsTIC26: Neoadjuvant 177Lu-PSMA-I&T Combined with Moderately Hypofractionated Radiotherapy in High-Risk Localized Prostate Cancer: A Multicentric Phase I TiTE-CRM Study (LU-EBRT)

ProsTIC 2026, LU-EBRT neoadjuvant lutetium-PSMA hypofractionated radiotherapy, lutetium-PSMA-I&T before radiotherapy high-risk localized prostat…

ProsTIC26: PETomics: Integrating PET Imaging and ctDNA Genomics via Deep Learning to Predict Response to 177Lu-PSMA‑617 in mCRPC Patients

ProsTIC 2026, PETomics deep learning PET imaging ctDNA lutetium-PSMA, multimodal deep learning predict lutetium-PSMA-617 response mCRPC, ctDNA P…

ProsTIC26: Appropriate Use of Lutetium PSMA in 2026

ProsTIC26, Metastatic Castration-Resistant Prostate Cancer, denosumab, 177Lu-PSMA-617, lutetium radioligand therapy, TheraP, ENZA-p, PSMAddition…

ProsTIC26: Will PSMA PET Replace Painful Prostate Biopsy? Yes

ProsTIC26, prostate cancer, PRECISION trial, PSMA PET, Prostate Biopsy, PRIMARY study, PRIMARY2 trial, prostate lymph-node staging.

ESMO 2023: Radiotherapy in Bladder Preservation

ESMO 2023 radiotherapy for the treatment of muscle invasive bladder cancer (MIBC).

ESMO 2023: Organ Preservation for Refractory Non-Muscle Invasive Bladder Cancer: A Surgeon's Perspective

ESMO 2023 options for organ preservation strategies for non-muscle invasive bladder cancer, challenges for BCG-unresponsive NMIBC, available int…

Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.

Background: Danish guidelines on muscle invasive bladder cancer (MIBC) recommend neoadjuvant chemotherapy (NAC) for non-metastatic patients fit…